Colin Biggin

Colin joined the Board in October 2019 as Managing Director and CEO after playing an instrumental role in enhancing and designing the Company’s product development and clinical programmes since he first joined the Company in January 2017.

Colin has over 15 years of radiopharmaceutical development and commercialisation experience. Colin previously served with Algeta ASA during the development and commercialisation of its product Xofigo® (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Colin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.

Colin holds a Bachelor of Science (Honours) and a PhD from the University of Glasgow.